热门资讯> 正文

第一三共（Daiichi Sankyo）和阿斯利康（AstraZeneca）的ENHERTI组合显示，HER 2阳性转移性乳腺癌的风险比THP降低44%

2025-09-24 14:40

Based on DESTINY-Breast09 phase 3 trial results, which showed ENHERTU plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival of greater than three years
If approved, Daiichi Sankyo and AstraZeneca's ENHERTU-based treatment approach would move into the first-line HER2 positive metastatic setting with potential to become a new standard of care

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。